MRVI: Maravai LifeSciences Holdings, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 340.42
Enterprise Value ($M) 565.87
Book Value ($M) 577.21
Book Value / Share 4.07
Price / Book 0.59
NCAV ($M) -1.89
NCAV / Share -0.01
Price / NCAV -180.21

Profitability (mra)
Return on Invested Capital (ROIC) -0.15
Return on Assets (ROA) -0.10
Return on Equity (ROE) -0.16

Liquidity (mrq)
Quick Ratio 6.65
Current Ratio 7.53

Balance Sheet (mrq) ($M)
Current Assets 429.15
Assets 1,008.24
Liabilities 431.04
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 259.19
Operating Income -72.68
Net Income -144.85

Cash Flow Statement (mra) ($M)
Cash From Operations 7.46
Cash from Investing -24.32
Cash from Financing -235.71

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
01-28 13G/A 12 West Capital Management LP 8.20 -17.27
11-14 13G/A Point72 Asset Management, L.P. 2.60 -44.53
11-13 13G/A Maravai Life Sciences Holdings 2, Llc 51.81 -7.06
11-08 13G BlackRock, Inc. 7.40 0.00
10-29 13G/A Millennium Management Llc 3.10 -39.31

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-21 1,858,386 11,644,192 15.96
2025-03-20 571,819 2,529,956 22.60
2025-03-19 1,111,413 4,932,030 22.53
2025-03-18 1,008,022 3,778,532 26.68
2025-03-17 374,071 2,291,588 16.32

(click for more detail)

Similar Companies
MNMD – Mind Medicine (MindMed) Inc. MRNA – Moderna, Inc.
MRSN – Mersana Therapeutics, Inc. MYGN – Myriad Genetics, Inc.
NBIX – Neurocrine Biosciences, Inc.


Financial data and stock pages provided by
Fintel.io